Advair Information

Advair contains medicines belonging to the class known as "long-acting beta 2-adrenergic agonists" (LABA), which are long-acting bronchodilator medicines. Bronchodilator medicines, such as LABAs, help to relax the muscles around the airways in the lungs. Wheezing (bronchospasm) happens when the muscles around the airways tighten. Even though LABAs decrease the frequency of asthma episodes, these medicines may make asthma episodes more severe when they occur.

In May of 2006 the FDA requested manufacturers of the Advair Diskus update their existing product labels with new warnings and a Medication Guide for patients to alert healthcare professionals and patients that these medicines may increase the chance of severe asthma episodes, and death when those episodes occur.

The information in FDA's proposed changes to the product labels explains that, even though Advair decreases the number of asthma episodes, the medicine may increase the chances of a severe asthma episode when they do occur. In one study, an increased number of people taking a Advair in addition to their usual asthma care died from their asthma compared to people taking a placebo in addition to their usual asthma care, although the number of asthma deaths in the study was small.

If you or someone you love has taken Advair and suffer from increased severe asthmatic episodes, contact our service today. We can help you get in touch with experienced and knowledgeable Advair attorneys who can help you protect your legal rights.